Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
8
×
life sciences
national blog main
national top stories
san francisco blog main
8
×
san francisco top stories
biotech
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
bristol-myers squibb
cancer
fda
intercept pharmaceuticals
nonalcoholic steatohepatitis
startups
alnylam pharmaceuticals
avexis
cancer drugs
cancer immunotherapy
celgene
colorectal cancer
What
disease
8
×
drug
known
liver
nash
roundup
approved
bio
cancer
fatty
medicine
medicines
new
news
race
according
adds
advanced
akcea
alliance
alnylam’s
alzheimer's
american
approval
areas
ash
bad
bff
big
biosciences
biotech
bio’s
blood
brain
brii
cancer’s
case
cases
centers
cigarettes
Language
unset
Current search:
disease
×
" san francisco blog main "
×
" boston top stories "
×
@xconomy.com
4 years ago
Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
5 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
ASH 2018: Three Up, Two Down As The Big Blood Disease Meeting Rolls On